The Q4 2016 earnings report formid cap proppant and fracking stock U.S. Silica Holdings Inc (NYSE: SLCA)is scheduled for after the market closes onWednesday (February 22nd). Proppant and fracking stockswere crushed by low oil prices; but with oil prices stabilizing, drilling activity coming back to the oil patches.
A technical chart for mid cap U.S. Silica Holdings shows a nice uptrend over the past year albeit that uptrend may have leveled off:
A long term performance chart shows U.S. Silica Holdings heading back up to 2014 highs followed by small capHi-Crush Partners LP (NYSE: HCLP) while small capCARBO Ceramics Inc (NYSE: CRR)is stillstruggling to survive:
market timing: North American Energy Partners, Inc.(NOA)
- [By Lisa Levin]
In trading on Tuesday, energy shares slipped by 1.36 percent. Meanwhile, top losers in the sector included Northern Oil & Gas, Inc. (NYSE: NOG), down 9 percent, and North American Energy Partners Inc.(USA) (NYSE: NOA), down 6 percent.
market timing: Vanguard Mega Cap Value ETF (MGV)
- [By Todd Shriber, ETF Professor]
Three of Vanguard's mega-cap equity ETFs now sport annual expense ratios of 0.07 percent, down from 0.09 percent. Those ETFs are the Vanguard Mega Cap ETF (NYSE: MGC), Vanguard Mega Cap 300 Growth Index ETF (NYSE: MGK) and the Vanguard Mega Cap Value Index ETF (NYSE: MGV).
market timing: Regions Financial Corporation(RF)
- [By Jon C. Ogg]
In the super-regional banks that are not money center banks, Regions Financial Corp. (NYSE: RF) was up 6.3% at $13.22, and Zions Bancorporation (NASDAQ: ZION) was last seen up 3.8% at $38.30. They would both do better with lower regulatory costs and be able to better compete against larger banks when their stress test results had not been as strong.
- [By Sean Williams]
Income investors often turn to bank stocks when looking for a steady dividend, but few offer the dividend growth potential of Southeastern regional bankRegions Financial (NYSE:RF).
market timing: Valeant Pharmaceuticals International Inc(VRX)
- [By Keith Speights]
It’s been a long time since Valeant Pharmaceuticals (NYSE:VRX) stock was in a legitimate uptrend. Despite the hiring of a new CEO last year to right the ship, Valeant’s share price has continued to fall.
- [By Chris Lange]
Valeant Pharmaceuticals International Inc. (NYSE: VRX) made waves early on Tuesday after the company offered a plethora of announcements. First the company gave an update on its late-stage psoriasis trial. Along with this success, Valeant reported the sale of a couple of its business segments, bringing in a sizable amount of cash.
- [By Ben Levisohn]
Today is not a good day for Valeant Pharmaceuticals International (VRX). After an announcement last night that it was hiring a sales force to push Salix products suggested that the unit might not be sold, reports emerged that suggest that a Salix sale was not going to happen. And now letters from the SEC have emerged that question Valeant’s use of non-GAAP measures. Wells Fargo’s David Maris and team explain the significance:
New SEC correspondence reveals potential problems with Valeant’s tax accounting and use of adjusted earnings metrics. In a series of letters made available by the SEC today, it appears the SEC has been questioning Valeant in regards to its tax reporting and disclosures, among other items. Recall that in our initiation of coverage report published in February 2016 we wrote extensively about potential problems arising from Valeant’s tax reporting, as well as its use of valuation allowances. It also appears from the correspondence that in response to concerns highlighted by the SEC, Valeant is re-assessing its current non-GAAP reporting and disclosures and is likely to present new measures and disclosures with its 2017 guidance and 4Q16 results, including a potential new adjusted net income measure. The correspondence between the SEC and Valeant can be found here: http://bit.ly/VUP1130 and here: http://bit.ly/VCOR1130
In additional news we consider disappointing, the Wall Street Journal is reporting that Valeant’s rumored talks to sell its Salix business to Takeda have broken down over disagreement in price. Separately, following yesterday’s market close, Valeant issued a press release announcing its initiation of a primary care salesforce for its Xifaxan and Relistor products. Valeant stated that the associated cost would not impact 2016 guidance; however, there was no indication of the potential impact to 2017.
Shares of Valeant Pharmaceuticals International have dropped 9% to $15.61 at
- [By Ben Levisohn]
Deutsche Bank’sGregg Gilbert andGreg Fraser cut their price target on Valeant Pharmaceuticals International (VRX) to $24 from $29, but say they “like the set-up for the stock in the short-term.” They explain why:
- [By Peter Graham]
Controversialmid capspecialty pharmastockValeant Pharmaceuticals International (NYSE: VRX) reportedQ1 2017 earnings before the market opened this morning with shares soaring in premarket trading. Valeant Pharmaceuticalshad beenwidelycriticized for pioneering the highly lucrative business model of acquiring pharmaceutical companies or their drugs, incorporating these drugs intoits sales and supply chain and thenjacking up the prices of these medications to levels contemporaneous with similar pharmaceutical products. In February 2016,the Companydisclosed that it was under investigation by the SEC and by the U.S. Attorney’s Offices for the Southern District of New York and then came under further criticism from politicians.
market timing: Telecom Italia S.P.A.(TI)
- [By Lisa Levin]
In trading on Friday, telecommunications services shares fell by 0.29 percent. Meanwhile, top losers in the sector included Telecom Italia SpA (ADR) (NYSE: TI), down 4 percent, and Internet Initiative Japan Inc. (ADR) (NASDAQ: IIJI), down 3 percent.
market timing: Wolverine World Wide, Inc.(WWW)
- [By Monica Gerson]
Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Monday’s regular session.
Pier 1 Imports Inc (NYSE: PIR) Dec16 5.0 Puts Sweep: 1191 @ ASK $0.80: 1354 traded vs 102 OI: $5.32 Ref Alcoa Inc (NYSE: AA) Jul16 9.5 Puts Sweep: 1494 @ ASK $0.13: 14k traded vs 6682 OI: $10.09 Ref Sarepta Therapeutics Inc (NASDAQ: SRPT) Jul16 10.0 Puts: 3536 @ ASK $0.50: 5506 traded vs 54k OI: Earnings 8/4 $22.50 Ref Tableau Software Inc (NYSE: DATA) Jul16 47.5 Puts Sweep: 837 @ ASK $0.30: 995 traded vs 37 OI: Earnings 8/3 $50.60 Ref Yandex NV (NASDAQ: YNDX) Aug16 18.0 Puts Sweep: 532 @ ASK $0.30: 2143 traded vs 78 OI: Earnings 7/28 Before Open $22.02 Ref Wolverine World Wide, Inc. (NYSE: WWW) Aug16 22.5 Puts: 719 @ ASK $1.35: 1032 traded vs 0 OI: Earnings 7/19 $22.22 Ref Conn's Inc (NASDAQ: CONN) Jan17 5.0 Puts Sweep: 605 @ ASK $0.85: 1355 traded vs 3132 OI: $7.16 Ref
Posted-In: Huge Put PurchasesNews Options Markets
- [By Matt Hogan]
SKX is also highly attractive in a relative basis when compared to several of its publicly traded peers: Foot Locker, Inc. (NYSE: FL), Deckers Outdoor Group (NYSE: DECK), Wolverine World Wide, Inc. (NYSE: WWW) and Columbia Sportswear Company (NASDAQ: COLM). The company's forward EBITDA multiple of 6.9x is equal or below all of the comparable companies: FL (6.9x), DECK (7.6x), WWW (10.1x) and COLM (10.8x).